| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Panchanan Maiti, Jayeeta Manna, Gary L Dunba. Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. Translational neurodegeneration. vol 6. 2019-11-20. PMID:29090092. |
gradual degeneration and loss of dopaminergic neurons in the substantia nigra, pars compacta and subsequent reduction of dopamine levels in striatum are associated with motor deficits that characterize parkinson's disease (pd). |
2019-11-20 |
2023-08-13 |
Not clear |
| Syed F Ali, Yossef Itzha. Effects of 7-Nitroindazole, an NOS Inhibitor on Methamphetamine-Induced Dopaminergic and Serotonergic Neurotoxicity in Mice Annals of the New York Academy of Sciences. vol 844. issue 1. 2019-11-20. PMID:29090810. |
effects of 7-nitroindazole, an nos inhibitor on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in mice methamphetamine (meth) is one of the major drugs of abuse that is postulated to cause neurotoxicity by depleting dopamine (da) and its metabolites, high-affinity da uptake sites, and the activity of tyrosine hydroxylase. |
2019-11-20 |
2023-08-13 |
mouse |
| R Sarojini, R Nagabhushanam, M Fingerma. In Vivo Effects of Dopamine and Dopaminergic Antagonists on Testicular Maturation in the Red Swamp Crayfish, Procambarus clarkii. The Biological bulletin. vol 189. issue 3. 2019-11-20. PMID:29244575. |
in vivo effects of dopamine and dopaminergic antagonists on testicular maturation in the red swamp crayfish, procambarus clarkii. |
2019-11-20 |
2023-08-13 |
Not clear |
| Pablo Garrido-Gil, Antonio Dominguez-Meijide, Rosario Moratalla, Maria J Guerra, Jose L Labandeira-Garci. Aging-related dysregulation in enteric dopamine and angiotensin system interactions: implications for gastrointestinal dysfunction in the elderly. Oncotarget. vol 9. issue 13. 2019-11-20. PMID:29541380. |
we showed a mutual regulation between the colonic dopaminergic system and ras using young and aged mice deficient for major angiotensin and dopamine receptors. |
2019-11-20 |
2023-08-13 |
mouse |
| Agnieszka A Kaczor, Justyna Żuk, Dariusz Matosiu. Comparative molecular field analysis and molecular dynamics studies of the dopamine D Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents. vol 27. issue 4. 2019-11-20. PMID:29576721. |
comparative molecular field analysis and molecular dynamics studies of the dopamine d the dopaminergic hypothesis of schizophrenia is the main concept explaining the direct reasons of schizophrenia and the effectiveness of current antipsychotics. |
2019-11-20 |
2023-08-13 |
Not clear |
| Philip Raskin, Anthony H Cincott. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary. Expert review of endocrinology & metabolism. vol 11. issue 2. 2019-11-20. PMID:30058874. |
in particular, a diminution of the circadian peak in dopaminergic input to the peri-scn facilitates the onset of fattening, insulin resistance and glucose intolerance while reversal of low circadian peak dopaminergic activity to the peri-scn via direct timed dopamine administration to this area normalizes the obese, insulin resistant, glucose intolerant state in high fat fed animals. |
2019-11-20 |
2023-08-13 |
human |
| Philip Raskin, Anthony H Cincott. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary. Expert review of endocrinology & metabolism. vol 11. issue 2. 2019-11-20. PMID:30058874. |
systemic circadian-timed daily administration of a potent dopamine d2 receptor agonist, bromocriptine, to increase diminished circadian peak dopaminergic hypothalamic activity across a wide variety of animal models of metabolic syndrome and type 2 diabetes mellitus (t2dm) results in improvements in the obese, insulin resistant, glucose intolerant condition by improving hypothalamic fuel sensing and reducing insulin resistance, elevated sympathetic tone, and leptin resistance. |
2019-11-20 |
2023-08-13 |
human |
| Delphine Charvin, Rossella Medori, Robert A Hauser, Olivier Rasco. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature reviews. Drug discovery. vol 17. issue 11. 2019-11-20. PMID:30262889. |
existing therapeutic strategies for managing parkinson disease (pd), which focus on addressing the loss of dopamine and dopaminergic function linked with degeneration of dopaminergic neurons, are limited by side effects and lack of long-term efficacy. |
2019-11-20 |
2023-08-13 |
Not clear |
| Zade R Holloway, Timothy G Freels, Josiah F Comstock, Hunter G Nolen, Helen J Sable, Deranda B Leste. Comparing phasic dopamine dynamics in the striatum, nucleus accumbens, amygdala, and medial prefrontal cortex. Synapse (New York, N.Y.). 2019-11-20. PMID:30317673. |
to summarize results, the present study found that the striatum and nac had increased stimulation-evoked phasic dopamine release, faster dopamine uptake (leading to restricted dopamine diffusion), weaker autoreceptor functioning, greater supply levels of available dopamine, and increased dopaminergic responses to dat blockade compared to the amygdala and mpfc. |
2019-11-20 |
2023-08-13 |
mouse |
| Smith, Hoepping, Johnson, Trzcinska, Kozikowsk. Dopaminergic agents for the treatment of cocaine abuse. Drug discovery today. vol 4. issue 7. 2019-11-20. PMID:10377510. |
because the pharmacological actions of cocaine stem laargely from its ability to block the dopamine transporter, many intervention strategies have focused on the dopaminergic pathway. |
2019-11-20 |
2023-08-12 |
Not clear |
| Sawaguch. The role of D1-dopamine receptors in working memory-guided movements mediated by frontal cortical areas. Parkinsonism & related disorders. vol 7. issue 1. 2019-11-20. PMID:11008191. |
like the striatum, the frontal motor cortices receive dopaminergic fibers from midbrain dopamine cells and contain high levels of dopamine receptors. |
2019-11-20 |
2023-08-12 |
monkey |
| b' Lled\\xc3\\xb. Dopamine agonists: the treatment for Parkinson\'s disease in the XXI century? Parkinsonism & related disorders. vol 7. issue 1. 2019-11-20. PMID:11008196.' |
moreover, as predicted by animal studies, on the long term, dopaminergic agonists induce significantly less motor complications than levodopa.in the last 2years, three new dopamine agonists have been launched, including ropinirole, pramipexole and cabergoline. |
2019-11-20 |
2023-08-12 |
Not clear |
| Rinn. Treatment of early Parkinson's disease. Parkinsonism & related disorders. vol 7. issue 1. 2019-11-20. PMID:11008197. |
in this context, recent double-blind long-term studies have confirmed the earlier results, suggesting that it appears advisable to initiate dopaminergic treatment in early pd by initially using a dopamine agonist and by adding levodopa when the benefit is no longer adequate with dopamine agonist alone. |
2019-11-20 |
2023-08-12 |
Not clear |
| Frim, Kan. Gene therapy for Parkinson's disease: review and update. Expert opinion on investigational drugs. vol 8. issue 10. 2019-11-20. PMID:11139810. |
current gene therapy models for pd are then described in two parts: genetic transfer of the biosynthetic enzymes for dopamine synthesis, and genetic transfer of the genes encoding neurotrophic factors protective for dopaminergic neurones. |
2019-11-20 |
2023-08-12 |
Not clear |
| R.A. Wise, K. Lee. Psychomotor-stimulant sensitization: a unitary phenomenon? Behavioural pharmacology. vol 4. issue 4. 2019-11-20. PMID:11224202. |
psychomotor sensitization can be produced by direct (apomorphine, bromocriptine) and indirect (amphetamine, cocaine) dopamine agonists that inhibit the firing of dopaminergic neurons and thus reduce impulse-dependent dopamine release. |
2019-11-20 |
2023-08-12 |
Not clear |
| R.A. Wise, K. Lee. Psychomotor-stimulant sensitization: a unitary phenomenon? Behavioural pharmacology. vol 4. issue 4. 2019-11-20. PMID:11224202. |
moreover, some treatments that cause dopaminergic activation and dopamine (da)-dependent locomotion fail to cause robust psychomotor sensitization. |
2019-11-20 |
2023-08-12 |
Not clear |
| M. Morelli, S. Fenu, A. Pinna, A. Cozzolino, A. Carta, G. Di Chiar. "Priming" to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message. Behavioural pharmacology. vol 4. issue 4. 2019-11-20. PMID:11224207. |
in adult rats bearing unilateral 6-hydroxydopamine (6-ohda) lesions of the ascending dopaminergic neurons, a single administration of a dopamine (da) receptor agonist results in strong sensitization ("priming") of contralateral turning in response to d2 and particularly d1 receptor agonists. |
2019-11-20 |
2023-08-12 |
rat |
| S Ferré, P Popoli, L Giménez-Llort, R Rimondini, C E. Müller, I Strömberg, S O. Ögren, K Fux. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism & related disorders. vol 7. issue 3. 2019-11-20. PMID:11331192. |
evidence for a role of dopaminergic neurotransmission in the motor effects of adenosine antagonists, such as caffeine, is reviewed, based on the existence of specific antagonistic interactions between specific subtypes of adenosine and dopamine receptors in the striatum. |
2019-11-20 |
2023-08-12 |
Not clear |
| S Ferré, P Popoli, L Giménez-Llort, R Rimondini, C E. Müller, I Strömberg, S O. Ögren, K Fux. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism & related disorders. vol 7. issue 3. 2019-11-20. PMID:11331192. |
at least a certain degree of dopaminergic activity is required to obtain adenosine antagonist-induced motor activation, with adenosine a(1) antagonists being the most sensitive and non-selective adenosine antagonists the most resistant to striatal dopamine depletion. |
2019-11-20 |
2023-08-12 |
Not clear |
| S Raypor. Glutamate is a cotransmitter in ventral midbrain dopamine neurons. Parkinsonism & related disorders. vol 7. issue 3. 2019-11-20. PMID:11331197. |
so it is surprising that the ventral midbrain dopamine neurons, which give rise to the dopaminergic pathway, may themselves also be glutamatergic. |
2019-11-20 |
2023-08-12 |
rat |